GLP-1 drugs linked to modest increase in hair loss risk for susceptible men

A recent study has found that glucagon‑like peptide‑1 (GLP‑1) receptor agonists—including the weight‑loss medications Ozempic, Wegovy and the newly approved Zepbound—may raise the risk of hair loss by about 7 percent in men who carry genetic markers for male‑pattern baldness. Researchers analyzed health records and genetic data to isolate the effect of these drugs from other factors, concluding that the increased incidence of thinning hair appears linked to the pharmacological action of GLP‑1 rather than to rapid weight reduction alone.

The findings suggest a biological connection between GLP‑1 activity and hair‑follicle physiology, expanding the known side‑effect profile of these increasingly popular treatments. While the absolute risk remains modest, clinicians are advised to consider patients’ family history of androgenic alopecia when prescribing GLP‑1 agonists and to monitor any changes in scalp health. Further investigation is needed to clarify the underlying mechanisms and to determine whether similar effects occur in other populations.